NCT06149559View on ClinicalTrials.gov

A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

June 8, 2026

Study Completion Date

August 17, 2026

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

rozanolixizumab

rozanolixizumab solution for injection

Trial Locations (11)

76208

WITHDRAWN

Mg0006 50574, Denton

Unknown

RECRUITING

Mg0006 40290, Bologna

RECRUITING

Mg0006 40144, Milan

RECRUITING

Mg0006 40733, Napoli

RECRUITING

Mg0006 20340, Fuchu-shi

RECRUITING

Mg0006 20339, Ōbu

RECRUITING

Mg0006 20343, Sagamihara

RECRUITING

Mg0006 40734, Lodz

RECRUITING

Mg0006 40155, Warsaw

RECRUITING

Mg0006 20081, Taipei

RECRUITING

Mg0006 20095, Taipei

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY